High PointBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma
Description
vTv Therapeutics Inc. , a clinical stage biopharmaceutical company focused on the development of cadisegliatin as an adjunctive therapy to insulin for the treatment of type 1 diabetes , today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately.
Company Information
Company
vTv Therapeutics Inc.
Location
4170 MENDENHALL OAKS PKWY
High Point, North Carolina, United States
About
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by cadisegliatin (TTP399), a potential adjunctive therapy to insulin for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and glioblastoma and other cancers and cancer treatment-related conditions.
Fundz sees it the moment vTv Therapeutics Inc. changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
High PointBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma